Chapter

Systemic therapy for advanced colorectal cancer

Fiona Collinson, Peter Hall, Mike Braun and Daniel Swinson

in Colorectal Cancer

Published on behalf of Oxford University Press

ISBN: 9780199590209
Published online May 2012 | e-ISBN: 9780191739675 | DOI: http://dx.doi.org/10.1093/med/9780199590209.003.0007

Series: Oxford Oncology Library

Systemic therapy for advanced colorectal cancer

Show Summary Details

Preview

• Over the past two decades the median overall survival for patients with advanced colorectal cancer has increased from 6 months without treatment to 2 years with modern systemic therapies • The standard chemotherapy armamentarium includes fluoropyrimidines, oxaliplatin and irinotecan delivered in two lines of treatment. Irinotecan and fluoropyrimidines have single agent activity but oxaliplatin is only effective in combination with a second drug • Infusional 5-fluorouracil can be substituted with capecitabine without loss of efficacy. Caution should be exercised in the elderly and in the presence of even modest renal impairment • Controversy persists on the worth of newer biological drugs targeting EGFR and VEGF • Current research aims to identify new agents and develop a tailored approach dependent on predictive clinicopathological and biological markers.

Chapter.  4170 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.